-

11:46:08 PM

AORT Stock News

AORT - Artivion Inc

05/23/23 8:04 AM

NYSE : AORT, BAX

Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration granted premarket application approval of PERCLOT Absorbable Hemostatic System...

RHEA-AI

very positive

05/04/23 4:05 PM

NYSE : AORT

earnings

Artivion Reports First Quarter 2023 Financial Results

Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis On-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022...

RHEA-AI

neutral

04/20/23 4:10 PM

NYSE : AORT

earnings

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial results will be released on Thursday, May 4, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer...

RHEA-AI

neutral

04/10/23 4:10 PM

NYSE : AORT

conferences

Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22 nd Annual Needham Virtual Healthcare Conference. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.

RHEA-AI

neutral

03/06/23 4:10 PM

NYSE : AORT

conferences

Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33 rd Annual Healthcare Conference. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.

RHEA-AI

neutral

02/16/23 4:05 PM

NYSE : AORT

earnings

Artivion Reports Fourth Quarter and Full Year 2022 Financial Results

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Asia Pacific and Latin American revenue grew 30% and 38%, respectively, on a constant currency basis compared to last year. During the fourth quarter, revenue growth was...

RHEA-AI

positive

02/02/23 8:30 AM

NYSE : AORT

earnings

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 financial results will be released on Thursday, February 16, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a...

RHEA-AI

neutral

11/08/22 4:25 PM

NYSE : AORT

conferences

Artivion to Participate in Upcoming Investor Conferences

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.Artivion's management team will present at the upcoming Stifel 2022

RHEA-AI

neutral

11/03/22 4:05 PM

NYSE : AORT

earnings

Artivion Reports Third Quarter 2022 Financial Results

Third Quarter and Recent Business Highlights:Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis On-X revenues increased 17% on a GAAP basis and 19% on a

RHEA-AI

positive

10/20/22 8:25 AM

NYSE : AORT

earnings

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes. On that day, the Company

RHEA-AI

neutral

AORT Data

IndustrySurgical and Medical Instrument Manufacturing
Websitecryolife.com
CeoJames Mackin
Security nameArtivion Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees1300
Address1655 Roberts Blvd NW
StateGeorgia
CityKennesaw
Zip30144-3632
CountryUS
Phone17704193355

About Artivion Inc

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica